Advance ZincTek Limited Overview
Advance ZincTek is a vertically integrated Australian specialty-materials manufacturer. Its core product is high-transparency, pharmaceutical-grade zinc oxide sold under the ZinClear brand, both as powders (ZinClear XP) and as ready-to-formulate dispersions in natural emollients. These are used as broad-spectrum "mineral" UV filters in sunscreens, cosmetics and topical pharmaceuticals. It also makes plate-like alumina effect powders (Alusion, rebranded White Sapphire) for colour cosmetics and is developing magnesium oxide and other cosmetic oxides. It operates from a TGA-licensed, solar-assisted facility in Brisbane and sells mainly through distributors. North America (US and Canada) generated 57% of FY2026 revenue. The investment case rests on the regulatory shift away from organic chemical UV filters (oxybenzone, homosalate, 4-MBC) toward mineral filters. Offsetting this are customer concentration, controlling-shareholder governance, US FDA compliance overhang, very slow inventory turnover, and a newly announced, unproven diversification into home battery storage.
Company's own description (latest Annual Report, FY2026)
The FY2026 Directors' Report describes the principal continuing activities as predominantly the manufacture of aluminium oxide powder (Alusion), zinc oxide dispersions and zinc oxide powder, collectively branded ZinClear, for the Personal Care Sector. It reports no significant change in the nature of activities. The operating-segment note (Note 23) identifies one reportable segment, Personal Care. That segment produces and distributes dispersions of mineral-only UV filters in cosmetic emollients for sunscreen, skincare and pharmaceutical formulations, plus alumina plate-like powders for cosmetic applications. The Corporate Governance Statement frames the Board's objective as creating long-term shareholder value through diversified product sales and development in cosmetics and sunscreen.
Independent characterisation
ANO is best understood as a niche active-pharmaceutical-ingredient (API) and cosmetic-ingredient manufacturer. It sits in the upstream-to-midstream part of the personal-care value chain:
-
Inputs. It buys raw zinc oxide feedstock and other raw materials from overseas suppliers, sometimes paying deposits in advance (FY2026 AR Note 11: A$172k of supplier deposits). It also buys carrier oils, many of them organic or vegan certified.
-
Conversion. It applies proprietary particle-engineering and dispersion know-how, which originated in mechanochemical processing research at the University of Western Australia and was scaled up through a 2000–2004 joint venture with Samsung Corning. The result is transparent, low-whitening zinc oxide powders and high-load dispersions (50% and 65% w/w zinc oxide grades are FDA NDC-listed).
-
Distribution. It sells through a network of specialty-chemical distributors in the US/Canada, Europe and Asia. In the US it moved from one exclusive distributor to four non-exclusive distributors during FY2024–FY2025. In Australia it also sells directly to contract sunscreen manufacturers.
-
Downstream (limited). It sells finished sunscreen products, mainly to the related party Veganic SKN Limited, and holds capitalised "ZinXation" end-formulation assets. Through a subsidiary established in FY2023, Sunscreen Safety Testing Laboratory Pty Ltd, it offers in-house SPF and safety testing support.
Business and revenue model
| Revenue model element | Assessment |
|---|---|
| Product vs service vs subscription vs licensing | About 100% product sales recognised at a point in time (AASB 15, FY2026 AR Note 5). No subscription revenue. Licence income was historically recognised (FY2023 accounting policy) but nothing material has been reported since. Testing services via SSTL are not separately disclosed |
| Pricing | Not publicly disclosed. Management states it adjusts selling prices for FX movements (no hedging). The FY2023 AR said EcoZinc launched at "increased pricing levels" |
| Customer type | B2B: specialty-chemical distributors, contract sunscreen manufacturers, cosmetic brand owners. Related-party B2B: Veganic SKN Limited (sunscreen products, A$1.28m in FY2026) |
| Customer concentration | FY2026: three customers at 23.97%, 20.4% and 11.78% of revenue (about 56% combined). FY2025: four customers at more than 11% each, 65% combined. FY2024: three customers, 50% (Note 23(b)) |
| End-markets | Sunscreen (OTC drug in US/Australia; cosmetic in EU), daily-wear skincare with SPF, colour cosmetics (alumina effect pigments), topical pharmaceuticals (zinc oxide as skin protectant). Management has identified adjacent agricultural, textile and rubber markets (FY2023 AR) and now home battery storage (FY2026 AR) |
| Geographic mix FY2026 | USA & Canada 57.2%; Australia 23.0%; Europe 10.8%; Rest of world 9.0% |
Value-chain position and moat sources
The defensible elements are (i) regulatory licences, namely Australian TGA manufacturing licensing and US FDA drug-establishment registration and NDC listings, which are costly and slow for new entrants to obtain; (ii) particle-dispersion know-how protected partly by patents ("Patented Dispersions" development asset, A$1.2m net book value at FY2026); and (iii) a "clean label" positioning (organic and vegan carrier oils, solar-powered "EcoZinc"). The main weaknesses are scale (about A$13m revenue against multinational competitors), dependence on a few distributors, and the commoditisation risk from lower-priced Asian zinc oxide imports, which management has publicly described as non-compliant in the Australian market (ASX release, 2 Oct 2025).
Strategy
Stated strategic themes (FY2025–FY2026 ARs, AGM Nov 2025), paraphrased
-
Grow distribution breadth, particularly non-exclusive multi-distributor models. Examples are the US move from 1 to 4 distributors and entry into countries where ANO is not represented (AGM 2025).
-
Ride regulatory displacement of chemical UV filters. Management actively campaigns on the health and environmental risks of oxybenzone, avobenzone, homosalate and 4-MBC, including LinkedIn campaigns reporting more than 8.2 million impressions (FY2025 AR). The FY2026 AR tabulates 4-MBC bans across the EU, UK, China, ASEAN, East Africa and Central America.
-
Embed AI across the business (sales analytics, formulation development, training). The company claims shorter development cycles and stable wages despite CPI (FY2025 and FY2026 Chairman's Letters).
-
Product diversification into adjacent oxides: High Purity White Sapphire, magnesium oxide, three new cosmetic oxides.
-
Operational efficiency: Perth closure, Brisbane consolidation, ERP/CRM implementation scheduled FY2026 (CRM, bill of materials, workflow scheduling, project management).
-
Supply-chain resilience: higher US stock against tariffs, possible build-up of key raw materials (FY2026 MD review), and a stated willingness to relocate production to the USA if tariffs required it (9 Jul 2025 release).
-
New growth vector — home battery storage (FY2027–FY2028). A pilot facility and equipment in FY2027, a pilot battery for testing in FY2028, using zinc oxide and high-purity alumina (ceramic separator coatings).
Strategic initiatives register (last 24 months)
| Initiative | Announced | Targets / metrics disclosed | Status (Oct 2026) |
|---|---|---|---|
| End US/Canada distributor exclusivity; 4 distributors | FY2024 Board decision (FY2025 AR) | US sales A$2.54m → A$6.15m (FY2025) → A$7.50m (FY2026) | Delivered |
| Perth facility and office closure | FY2024 decision; AGM Nov 2025 | About A$750k savings FY2025; further savings FY2026 | Delivered |
| White Sapphire Matte/Glow relaunch | FY2025 | More than 200 samples; test orders received | Revenue still declining (A$111k FY2026) |
| High Purity White Sapphire | FY2025 | 16+ applications; 600+ potential customers; launch 2026 | Development; not launched per FY2026 AR |
| Magnesium oxide | FY2025 | Marketing FY2026 | No revenue disclosed |
| Three new cosmetic oxides | FY2025 | Trials | Development |
| AI adoption | FY2025 | Qualitative | Ongoing |
| ERP/CRM software | FY2025 | Implementation FY2026 | Not reported as complete |
| Capital management (2c capital return) | Jun 2025 flagged; Feb 2026 executed | A$1.226m | Completed 25 Feb 2026 |
| Raw-material stock build | FY2026 AR | Not quantified | Under Board consideration |
| Home battery storage | FY2026 AR (31 Aug 2026) | Pilot facility FY2027; prototype FY2028 | Pre-development; no capex budget disclosed |
| Sustainability (PV, organic/vegan inputs, EcoZinc) | FY2023 onward | 50% of FY2023 production on PV power | Ongoing; no formal targets |
Medium-term financial targets / guidance
ANO does not publish medium-term financial targets. Its only quantitative guidance has been short-dated, unaudited pre-announcements:
-
10 Jun 2025: expected FY2025 PBT of about A$1.95m (the "A$2.7m turnaround"); actual was A$2.024m.
-
20 Jul 2026: FY2026 unaudited PBT A$2.294m; audited A$2.247m, 2% lower.
The standing forward-looking statement in each AR is only that the Group has a solid platform from which to grow sales, improve margins and deliver profitability.
Products & Services
All products sit within the single Personal Care segment. Pricing is not publicly disclosed for any line.
Product Portfolio
| Product / brand | Description & key specifications | Target customer | Launch / latest version | Status & notes |
|---|---|---|---|---|
ZinClear XP (powder) | High-transparency, pharmaceutical-grade zinc oxide powder used as a broad-spectrum UVA/UVB mineral filter. Shelf life extended from 3 to 5 years (FY2023 AR). FDA NDC listing shows 100% zinc oxide powder (labeler code 83679) | Sunscreen and cosmetics formulators, contract manufacturers | Long-standing; 5-year shelf life from FY2023 | Core product. Manufacturing cost of XP powder cut 15% in FY2023 |
ZinClear dispersions | Pre-dispersed zinc oxide in cosmetic emollients. FDA NDC listings for 50% w/w and 65% w/w zinc oxide "solutions" in pack sizes from 1 kg bottles to 200 kg drums and 1,260 kg containers (openFDA via HelloPharmacist). Carrier oils include sunflower and coconut variants (development-asset names, FY2023 AR); expansion to five organic/vegan base oils planned (FY2023 AR) | Brand owners wanting easy-to-formulate, low-whitening mineral sunscreens; organic/vegan brands | Ongoing; new oil bases FY2024–25 | Core product. Capitalised "Patented Dispersions" asset A$1.42m cost |
EcoZinc | Premium ZinClear grade manufactured "100% powered by the sun" using on-site PV (FY2023 AR) | Sustainability-positioned brands | Launched FY2023/FY2024 | Sold at premium pricing via distributors (per company) |
ZinXation | End-formulation (finished sunscreen) technology and recipes; capitalised development asset (A$783k cost; A$604k net, FY2026) | Australian contract manufacturers; brand owners; Veganic SKN | Original formulations before FY2018; asset additions FY2025 | Linked to sunscreen product sales |
Finished sunscreen products | Zinc-based sunscreen formulations supplied finished, mainly to Veganic SKN Limited (related party) | Related-party brand owner; selected third parties | Material from FY2023 | FY2026 revenue A$1.463m |
Alusion / White Sapphire (Glow, Matte) | Plate-like alumina (aluminium oxide) effect powders for colour cosmetics. "Matte" and "Glow" variants; more than 200 samples distributed in early 2025 (FY2025 AR) | Colour cosmetics manufacturers (Asia, Europe) | Alusion legacy; White Sapphire Matte/Glow 2025 | Revenue collapsed after Sapphire Matte problem (Apr 2025) |
High Purity White Sapphire | High-purity alumina. More than 16 potential applications identified, 3 requiring TGA-licensed manufacturing; addressable base of 600+ potential customers (company claim, FY2025 AR). Also targeted as ceramic separator coating for batteries (FY2026 AR) | Cosmetics, pharma, battery materials | Trials July 2025 needed refinement; launch targeted 2026 (AGM Nov 2025) | Development stage |
Magnesium oxide | Cosmetic/pharma-grade MgO; trials successful, marketing to begin FY2026 (FY2025 AR) | Existing ZinClear customers | FY2026 | No revenue separately disclosed |
Three new cosmetic oxides | Raw-material sourcing for trials begun FY2025; aimed only at the cosmetic sector, to complement ZinClear | Cosmetic formulators | Development | Not named |
Sunscreen Safety Testing Laboratory (SSTL) | Testing centre for ZinClear-based products (opened about Sep 2023 per FY2023 AR plan) | Customers formulating with ZinClear | FY2024 | No separate revenue disclosed |
Formulation support / dermatologist endorsement programme | Formulation recipes using ZinClear XP; access to endorsement by a named Queensland dermatologist (FY2023 AR Board initiatives) | Brand owners | FY2024–25 | Marketing service, not separately monetised |
Industrial zinc oxide (exploratory) | Agricultural, textile and rubber applications. Company sizes these US markets at about US$800m combined, against about US$600m for US pharmaceutical-grade zinc oxide (FY2023 AR, company estimate) | Industrial distributors | Exploratory since FY2023 | No disclosed revenue |
Residential battery energy storage (planned) | Full-process pilot from electrode slurry to battery pack, using zinc oxide and high-purity alumina expertise; pilot facility construction and equipment ordering in FY2027; prototype battery testing in FY2028 (FY2026 AR) | Home energy storage market | Announced Aug 2026 | Pre-development; no budget disclosed |
Financial Narrative
Sources: audited Annual Reports FY2022–FY2026 (FY2022 figures from FY2023 AR comparatives; FY2024 from FY2025 AR comparatives). Currency A$k unless stated.
Income statement
Notes: EBITDA = PBT + depreciation (PP&E and ROU) + amortisation + lease interest + finance costs. EBIT = PBT + interest expense. Both include other income (R&D tax incentive, FX gains and the FY2022 A$831k related-party IP sale gain). FY2023 shows both "lease interest" (A$110k) and "finance costs" (A$102k) on the face of the P&L; both are added back as reported. Tax expense is almost entirely deferred (non-cash) because of carried-forward losses.
Margins and growth
Revenue CAGR. FY2022→FY2026 (4 years): +1.2% p.a. FY2021→FY2026 (5 years, from the A$6.52m trough): +15.0% p.a. FY2020 (A$17.97m peak)→FY2026: –5.1% p.a. The starting point drives the answer: ANO has not regained its FY2020 revenue peak.
Balance sheet (30 June)
FY2024 borrowings of A$320k were an interest-free, on-demand loan from an entity associated with Lev Mizikovsky, repaid in FY2025 (FY2025 AR Note 26). The company states it has no external debt.
Cash flow
The FY2026 cash-flow statement labels the A$1.226m outflow "Payments from shares buyback", but the equity note and Directors' Report describe it as a 2-cent-per-share return of capital approved by shareholders. The analyst treats it as a capital return; no shares were cancelled (share count rose by 33,750 employee shares).
Ratio analysis
Invested capital = equity + lease liabilities + borrowings − cash. DIO uses "raw materials and consumables used" as a cost-of-goods proxy. Because labour and overheads are absorbed into inventory, true COGS is higher and true DIO somewhat lower, but the order of magnitude (more than 2 years of stock) is robust.
Commentary on trends, inflections and drivers
Revenue: cyclical, distributor-driven, not yet structurally growing. Revenue has moved in a "boom–bust–recovery" pattern driven by distributor ordering rather than end-demand. The FY2020 peak (A$18.0m) reflected heavy distributor stocking. FY2021 collapsed to A$6.5m as that stock unwound. FY2022–FY2023 recovered to A$12.5–13.7m, but FY2023 included an A$533k timing benefit: a US distributor bought stock in June 2022 on deferred terms (FY2023 AR "Adjusted Results"). FY2024 fell 32% to A$9.3m, with US/Canada down 62%. The Board's response, ending US exclusivity and moving to four distributors, drove a 141% US rebound in FY2025 and a further 23% in FY2026. FY2026 revenue (A$13.1m) is still 4.6% below FY2023 and 27% below FY2020. Management itself warned in FY2023 that disclosed sales orders were an unreliable forward indicator and stopped publishing them.
Gross margin: resilient and improving. Derived gross margin of 58–61% in four of five years points to genuine pricing power for pharmaceutical-grade transparent zinc oxide. The FY2023 Chairman noted stable gross margins without price increases, and FY2026 reached 60.8%. The FY2024 dip to 48.5% reflects under-absorption on lower volumes and the White Sapphire issue. Because labour and overheads are capitalised into inventory, the "raw materials used" line understates full COGS. Third-party aggregators report a different cost of revenue for FY2024 (A$8.47m per Kalkine/Stoxray data), which suggests they include absorbed overheads or inventory movements. Figures are not directly comparable.
Operating leverage and cost reset. Closing the Perth (Welshpool) facility and consolidating in Brisbane saved about A$750k in FY2025 (Chairman's Letter). PP&E depreciation has been flat at about A$1.2m. In FY2026, operating cost lines grew faster than revenue: corporate costs rose from A$171k to A$469k, consulting from A$120k to A$262k, other operating expenses from A$584k to A$1,109k (including a A$289k FX loss), and superannuation by 32%. As a result, EBITDA margin slipped from 32.9% to 31.3% despite gross-margin expansion. Part of the cost growth plausibly relates to FDA remediation and US regulatory work, but the AR does not attribute it.
Earnings quality. About 90% of the gap between EBITDA and NPAT is non-cash depreciation and deferred tax. ANO pays no cash income tax because of A$4.69m of tax-effected carried-forward losses (FY2026 Note 15). Other income (R&D incentive of about A$0.5m a year) is about 22% of PBT in FY2026, so underlying operating profit is lower than headline PBT suggests. The H1/H2 split is also notable. H1 FY2026 NPAT was A$1,158k (Appendix 4D), leaving only A$351k for H2 on revenue of A$6,449k. That points to H2 cost pressure (FX loss, consultants, inventory provision increase of A$132k).
Balance sheet: asset-heavy, cash-light. Equity of A$36m is dominated by inventory (A$11.3m), PP&E (A$11.3m) and deferred tax assets (A$5.4m). Cash has been below A$1.4m at every year-end in the window, and only A$0.6m at FY2026. That is unusually thin for a company that also returned A$1.2m of capital and is announcing a battery pilot plant. Liquidity rests on receivables and the ability to slow inventory production. There is no external debt facility disclosed.
Inventory: the central analytical issue. Inventory of A$11.3m is equivalent to about 0.86x annual revenue and, on raw-material cost, more than two years of consumption. The auditor has flagged inventory valuation and existence as a key audit matter in every year reviewed. Management justifies elevated stock by (a) faster delivery than competitors, (b) holding stock in the US to pre-empt tariffs, and (c) potential raw-material shortages. In the FY2026 AR the Board said it may divert "excess cash" to increasing raw-material stocks, which is hard to reconcile with a A$0.6m cash balance. The FY2026 provision for impairment more than doubled to A$235k. Any NRV reassessment, product shelf-life issue or regulatory restriction on US sales would therefore hit equity directly.
Cash flow. OCF has been positive every year and reached a five-year high of A$3.35m in FY2026, helped by inventory drawdown (A$573k) and prepayment unwinds. After PP&E capex, capitalised development and lease principal, discretionary free cash flow was about A$1.2m in FY2026. That roughly matches the capital return, which explains why year-end cash was unchanged.
Capital efficiency is weak. ROE of 4–7% in good years and ROIC around 4–5% sit well below any reasonable cost of equity for an illiquid micro-cap. The persistent gap between NAV per share (57.5c) and share price (71–80c) is modest, but the market is clearly not paying for growth.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Ownership | Function (analyst characterisation) |
|---|---|---|---|
Advance ZincTek Limited | Australia | Parent | Listed head entity; manufacturing; TGA/FDA licence holder |
Antaria Pty Ltd | Australia | 100% | Legacy operating subsidiary (former Antaria brand) |
Sunscreen Safety Testing Laboratory Pty Ltd | Australia | 100% (established FY2023) | SPF/safety testing support for ZinClear-based formulations |
Antaria, Inc | USA | 100% | US commercial entity; Dallas TX warehouse |
Antaria Europe, B.V. | Netherlands | 100% | EU commercial entity; s'Heerenberg third-party warehouse (Mainfreight) |
Product Lines
| Product line (AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ZinClear zinc oxide powders & dispersions (AUD K) | 11,456 | 11,892 | 7,830 | 11,100 | 11,537 |
Alusion / White Sapphire alumina (AUD K) | 983 | 945 | 1,020 | 150 | 111 |
Sunscreen products (AUD K) | 65 | 908 | 470 | 389 | 1,463 |
Total revenue (AUD K) | 12,504 | 13,745 | 9,320 | 11,639 | 13,111 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ZinClear share of revenue (%) | 91.6 | 86.5 | 84.0 | 95.4 | 88.0 |
Alusion/White Sapphire share of revenue (%) | 7.9 | 6.9 | 10.9 | 1.3 | 0.8 |
Sunscreen products share of revenue (%) | 0.5 | 6.6 | 5.0 | 3.3 | 11.2 |
ZinClear YoY growth (%) | 0 | 3.8 | -34.2 | 41.8 | 3.9 |
Alusion/White Sapphire YoY growth (%) | 0 | -3.9 | 7.9 | -85.3 | -26.0 |
Sunscreen products YoY growth (%) | 0 | 1,297 | -48.2 | -17.2 | 276 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric (AUD K unless %) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment (= group) revenue (AUD K) | 12,504 | 13,745 | 9,320 | 11,639 | 13,111 |
Segment (= group) profit before tax (AUD K) | 3,682 | 2,291 | -990 | 2,024 | 2,247 |
Segment PBT margin (%) | 29.4 | 16.7 | -10.6 | 17.4 | 17.1 |
Revenue YoY growth (%) | 91.7 | 9.9 | -32.2 | 24.9 | 12.6 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD K) | 12,504 | 13,745 | 9,320 | 11,639 | 13,111 |
Other income incl. R&D incentive (AUD K) | 1,750 | 895 | 684 | 676 | 643 |
Raw materials & consumables (AUD K) | 5,166 | 5,677 | 4,801 | 4,927 | 5,145 |
Gross profit, derived = revenue less raw materials (AUD K) | 7,338 | 8,068 | 4,519 | 6,712 | 7,966 |
Employee benefits incl. super (AUD K) | 1,868 | 2,671 | 1,836 | 1,894 | 1,996 |
Depreciation PP&E (AUD K) | 999 | 1,196 | 1,262 | 1,206 | 1,200 |
Depreciation right-of-use (AUD K) | 495 | 509 | 513 | 456 | 425 |
Amortisation (AUD K) | 66 | 71 | 62 | 91 | 180 |
Interest expense, lease + finance (AUD K) | 204 | 212 | 89 | 56 | 52 |
EBITDA, derived (AUD K) | 5,446 | 4,279 | 936 | 3,833 | 4,104 |
EBITDA excluding other income, derived (AUD K) | 3,696 | 3,384 | 252 | 3,157 | 3,461 |
EBIT / operating income, derived (AUD K) | 3,886 | 2,503 | -901 | 2,080 | 2,299 |
Profit before tax (AUD K) | 3,682 | 2,291 | -990 | 2,024 | 2,247 |
Income tax expense (benefit) (AUD K) | 1,491 | 628 | -87 | 786 | 738 |
Net profit after tax (AUD K) | 2,191 | 1,663 | -903 | 1,238 | 1,509 |
Basic EPS (A$ cents) | 3.58 | 2.69 | -1.45 | 1.98 | 2.41 |
Diluted EPS (A$ cents) | 3.58 | 2.69 | -1.45 | 1.98 | 2.41 |
Weighted avg shares (millions) | 61.22 | 61.62 | 62.45 | 62.50 | 62.65 |
Dividends paid per share in year (A$ cents) | 0 | 6 | 0 | 0 | 0 |
Capital return per share (A$ cents) | 0 | 0 | 0 | 0 | 2 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 91.7 | 9.9 | -32.2 | 24.9 | 12.6 |
Gross margin, derived (%) | 58.7 | 58.7 | 48.5 | 57.7 | 60.8 |
EBITDA margin (%) | 43.6 | 31.1 | 10.0 | 32.9 | 31.3 |
EBITDA margin excl. other income (%) | 29.6 | 24.6 | 2.7 | 27.1 | 26.4 |
EBIT margin (%) | 31.1 | 18.2 | -9.7 | 17.9 | 17.5 |
PBT margin (%) | 29.4 | 16.7 | -10.6 | 17.4 | 17.1 |
Net margin (%) | 17.5 | 12.1 | -9.7 | 10.6 | 11.5 |
Income Statement
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (AUD K) | 4,148 | 5,097 | 6,584 | 12,260 | 17,967 | 6,523 | 12,504 | 13,745 | 9,320 | 11,639 | 13,111 |
Profit before tax (AUD K) | -452 | 561 | 1,125 | 3,381 | 7,461 | 265 | 3,682 | 2,291 | -990 | 2,024 | 2,247 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD K) | 38,268 | 39,062 | 37,741 | 38,040 | 37,815 |
Cash & equivalents (AUD K) | 1,331 | 325 | 163 | 629 | 618 |
Trade & other receivables (AUD K) | 4,439 | 3,833 | 2,358 | 3,277 | 4,256 |
of which trade receivables, gross (AUD K) | 4,017 | 2,621 | 1,091 | 2,148 | 3,028 |
Inventories (AUD K) | 10,891 | 13,066 | 12,734 | 11,887 | 11,314 |
Property, plant & equipment (AUD K) | 10,478 | 12,004 | 11,941 | 11,617 | 11,329 |
Right-of-use assets (AUD K) | 2,382 | 2,000 | 1,487 | 1,235 | 866 |
Deferred tax assets (AUD K) | 5,514 | 5,341 | 5,943 | 5,652 | 5,410 |
Development assets / intangibles (AUD K) | 1,943 | 1,975 | 2,669 | 3,114 | 3,671 |
Goodwill (AUD K) | 0 | 0 | 0 | 0 | 0 |
Short-term debt incl. current leases (AUD K) | 454 | 513 | 735 | 418 | 513 |
Long-term debt, non-current leases (AUD K) | 2,084 | 1,665 | 1,250 | 983 | 357 |
Total debt incl. leases (AUD K) | 2,538 | 2,178 | 1,985 | 1,401 | 870 |
Bank / related-party borrowings (AUD K) | 0 | 0 | 320 | 0 | 0 |
Net debt incl. leases (AUD K) | 1,207 | 1,853 | 1,822 | 772 | 252 |
Net debt excl. leases (AUD K) | -1,331 | -325 | 157 | -629 | -618 |
Total liabilities (AUD K) | 3,279 | 3,779 | 3,361 | 2,271 | 1,760 |
Total equity (AUD K) | 34,989 | 35,283 | 34,380 | 35,769 | 36,055 |
Working capital (AUD K) | 16,947 | 15,854 | 13,688 | 15,214 | 15,245 |
Net assets per share (A$ cents) | 57.06 | 56.50 | 55.05 | 57.09 | 57.52 |
Net tangible assets per share (A$ cents) | 45.15 | 45.08 | 41.55 | 43.36 | 43.03 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | 1,619 | 4,421 | 2,239 | 2,675 | 3,345 |
Capex, PP&E (AUD K) | 2,493 | 2,737 | 1,451 | 887 | 933 |
Capitalised development spend (AUD K) | 715 | 75 | 757 | 536 | 736 |
Lease principal repayments (AUD K) | 458 | 514 | 513 | 466 | 491 |
Free cash flow = OCF less PP&E capex (AUD K) | -874 | 1,684 | 788 | 1,788 | 2,412 |
Free cash flow after development & leases (AUD K) | -2,047 | 1,095 | -482 | 786 | 1,185 |
Dividends paid in cash (AUD K) | 0 | 1,420 | 0 | 0 | 0 |
Capital return paid (AUD K) | 0 | 0 | 0 | 0 | 1,226 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Equity raised (AUD K) | 2,442 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 7.0 | 4.7 | -2.6 | 3.5 | 4.2 |
ROA on closing assets (%) | 5.7 | 4.3 | -2.4 | 3.3 | 4.0 |
ROIC, NOPAT at 30% over invested capital (%) | 7.5 | 4.7 | -1.7 | 4.0 | 4.4 |
Current ratio (x) | 17.9 | 9.4 | 7.8 | 13.6 | 12.8 |
Debt incl. leases to equity (x) | 0.07 | 0.06 | 0.06 | 0.04 | 0.02 |
Net debt incl. leases to EBITDA (x) | 0.22 | 0.43 | 1.95 | 0.20 | 0.06 |
Interest coverage, EBIT over interest (x) | 19.0 | 11.8 | -10.1 | 37.1 | 44.2 |
Asset turnover, revenue over closing assets (x) | 0.33 | 0.35 | 0.25 | 0.31 | 0.35 |
Days inventory outstanding, on raw materials used (days) | 769 | 840 | 968 | 881 | 803 |
Days sales outstanding, trade receivables (days) | 117 | 70 | 43 | 67 | 84 |
Days payables outstanding, trade payables (days) | 30 | 71 | 72 | 34 | 34 |
Cash conversion cycle (days) | 856 | 839 | 939 | 914 | 853 |
Revenue by Region
| Region (AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Australia (AUD K) | 1,595 | 2,503 | 1,675 | 2,211 | 3,013 |
United States & Canada (AUD K) | 7,594 | 6,723 | 2,539 | 6,115 | 7,495 |
Europe (AUD K) | 2,247 | 2,459 | 2,772 | 1,056 | 1,421 |
Rest of world, mainly Asia (AUD K) | 1,068 | 2,060 | 2,334 | 2,257 | 1,182 |
Total (AUD K) | 12,504 | 13,745 | 9,320 | 11,639 | 13,111 |
Region Margins & Growth (%) and Revenue by Region (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Australia YoY growth (%) | 0 | 56.9 | -33.1 | 32.0 | 36.3 |
US & Canada YoY growth (%) | 0 | -11.5 | -62.2 | 140.8 | 22.6 |
Europe YoY growth (%) | 0 | 9.4 | 12.7 | -61.9 | 34.6 |
Rest of world YoY growth (%) | 0 | 92.9 | 13.3 | -3.3 | -47.6 |
Australia share (%) | 12.8 | 18.2 | 18.0 | 19.0 | 23.0 |
US & Canada share (%) | 60.7 | 48.9 | 27.2 | 52.5 | 57.2 |
Europe share (%) | 18.0 | 17.9 | 29.7 | 9.1 | 10.8 |
Rest of world share (%) | 8.5 | 15.0 | 25.0 | 19.4 | 9.0 |
Share Price and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 2.02 | 1.77 | 0.72 | 0.83 | 0.80 |
Net assets per share (A$ cents) | 57.06 | 56.50 | 55.05 | 57.09 | 57.52 |
NTA per share (A$ cents) | 45.15 | 45.08 | 41.55 | 43.36 | 43.03 |
Basic EPS (A$ cents) | 3.58 | 2.69 | -1.45 | 1.98 | 2.41 |
Cash distributions per share in year (A$ cents) | 0 | 6 | 0 | 0 | 2 |
Share Price History
| Period | Price change | Basis |
|---|---|---|
1 year | –3.6% | 30 Jun 2025 (A$0.83) → 30 Jun 2026 (A$0.80) |
1 year (to mid-Aug 2026) | –35% | Fintel; starting point is the July–August 2025 spike to about A$1.10–1.16 |
3 years | –54.8% | 30 Jun 2023 (A$1.77) → 30 Jun 2026 |
5 years | –78.4% | 30 Jun 2021 (A$3.70) → 30 Jun 2026 |
Latest | A$0.71 | 1 Sep 2026 (InvestSMART); trading is very thin, with many zero-volume days |
Valuation Multiples
| Multiple | ANO | Peers |
|---|---|---|
Market capitalisation | About A$44.5m | — |
Enterprise value (incl. leases, less cash) | About A$44.8m | — |
P/E (trailing) | 29.5x | Not comparable (no listed pure-play peers) |
EV/EBITDA | 10.9x | Not comparable |
EV/Sales | 3.4x | Not comparable |
P/B | 1.23x | — |
P/NTA | 1.65x | — |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None. Not covered by any broker (Market Index; Simply Wall St: 0 analysts) |
Dividend history | 6c unfranked dividend paid 22 Mar 2023 (ex-date 2 Mar 2023); no dividends FY2024–FY2026 |
Dividend policy | Not formally stated |
Capital return | 2c per share (A$1.226m) paid 25 Feb 2026 |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | No external debt. Lease liabilities: A$543k within 1 year; A$364k in 1–5 years (undiscounted, FY2026 Note 27) |
Analyst Conclusions
Management guidance
No formal FY2027 guidance has been issued. The FY2026 Annual Report describes rising global enquiries, regulatory tailwinds from 4-MBC and homosalate restrictions, a possible raw-material stock build, and the start of a home battery storage pilot in FY2027. Consensus forecasts do not exist.
Bull case
-
Regulatory tailwind is real and dated. EU, UK, China and ASEAN 4-MBC bans and homosalate limits force reformulation in 2026–2028, and zinc oxide is a natural substitute.
-
The distribution reset has proven operating leverage. US/Canada revenue nearly tripled in two years (A$2.54m to A$7.50m), and gross margin reached 60.8%.
-
Asset backing limits downside. The price sits at 1.23x book value; there is no debt; and A$4.69m of tax losses shield future profits.
Bear case
-
The FDA overhang is unresolved and undisclosed in the Annual Report. The US is 57% of revenue; GMP findings and an import alert could curtail sales once warehouse stock is depleted.
-
Working capital ties up most of the company's value. Inventory of A$11.3m (about 800 days) and cash of A$0.6m leave little room for error, and an inventory write-down would hit equity directly.
-
Governance and capital allocation. There is no independent board oversight; related-party revenue (Veganic SKN) drove FY2026 sunscreen growth; and the battery project is an unbudgeted pivot far outside the core competency.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| FDA import alert / GMP remediation status | Any time | Formal removal or escalation (warning letter) |
| 2026 AGM | About November 2026 | Battery project budget; capital management; board renewal |
| Q1 FY2027 revenue update (if issued, as in Oct 2025) | October 2026 | US revenue trend after the import alert |
| H1 FY2027 results | 26 Feb 2027 (calendar) | Inventory, cash, related-party share of revenue |
| White Sapphire HP and magnesium oxide launches | 2026–2027 | First disclosed revenue |
| Battery pilot facility spending | FY2027 | Capex size and funding source |
| US tariff policy | Ongoing | Any removal of the zinc oxide exemption |
Analyst verdict
Advance ZincTek is a genuinely profitable, debt-free niche manufacturer with a defensible technical and regulatory position in transparent zinc oxide. It is also a company whose financial profile has failed to compound. FY2026 revenue of A$13.1m is below FY2023 and 27% below the FY2020 peak. Returns on equity and invested capital of about 4% are well below the cost of capital, and the balance sheet ties up more than two years of materials in inventory while holding only A$0.6m of cash.
The FY2025–FY2026 recovery is real but narrow. It rests on a successful US distribution restructure, high gross margins, and a growing but related-party-dependent sunscreen line. The regulatory backdrop, with 4-MBC bans, homosalate limits and TiO2 scrutiny, is the strongest structural tailwind the company has had in a decade, and management correctly identifies it.
Against this, three issues dominate the risk profile. First, the US FDA GMP findings and import alert in late 2025 and early 2026 bear directly on the market that generates 57% of revenue, yet the FY2026 Annual Report omits them from its risk disclosures. That gap is a serious transparency concern. Second, governance is weak: a three-person board without independent directors oversees extensive related-party transactions with entities controlled by a 65% shareholder. Third, the newly announced home battery project is a capital-allocation pivot of uncertain scale and logic for a company of this size.
At A$0.71 the shares trade at about 1.2x book value, 11x EV/EBITDA and about 30x trailing earnings. That valuation neither prices in material growth nor discounts a severe regulatory outcome. With minimal liquidity (free float of about 16%) and no broker coverage. On balance the analyst's stance is neutral with a negative bias, pending clear public disclosure on the FDA matters and a funded, budgeted plan for the battery initiative.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure (start) | Prior / other roles | Education / qualifications |
|---|---|---|---|---|
Lev Mizikovsky | Non-Executive Chairman; member of all committees | Director since 10 Apr 2015 (aggregator date) | Founder (July 1989) and Executive Chairman of Tamawood Limited (ASX: TWD); Executive Chairman of SenterpriSys Limited (NSX: SPS) and Veganic SKN Limited; formerly a substantial holder in Lindsay Australia (per FY2023 AR) | FAICD (Fellow of AICD since 1977) |
Rade Dudurovic | Non-Executive Director; Chair of Audit Committee; Chair of Nomination & Remuneration Committee | Director since 2 Nov 2011 (aggregator date) | Private equity background in industrial and branded consumer manufacturing and distribution, particularly in Asia; NED of Tamawood (from 31 May 2024), SenterpriSys and Veganic SKN | B.Com (Hons), LLB (Hons), CPA, Senior Fellow FINSIA |
Geoff Acton | Managing Director; joint Company Secretary (since 13 Jul 2015); member of Audit and Risk committees | MD since 16 Mar 2016 (aggregator date) | More than 20 years with the Tamawood Group as Director, CFO and Company Secretary; founded Tamawood's Renewable Energy Certificate trading business (2004); NED of Veganic SKN | B.Com, CA, GAICD |
Narelle Lynch | Joint Company Secretary | Since 9 Aug 2017 | — | Cert Gov Prac |
Directors' Remuneration
| KMP (AUD) | Cash salary/fees FY2026 | Bonus FY2026 | Super FY2026 | LSL FY2026 | Total FY2026 | Total FY2025 | Total FY2024 | Total FY2023 |
|---|---|---|---|---|---|---|---|---|
Lev Mizikovsky (Chair) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Rade Dudurovic (NED) | 62,004 | 0 | 0 | 0 | 62,004 | 62,004 | 62,400 | 50,000 |
Geoff Acton (MD) | 292,500 | 0 | 6,558 | 870 | 299,928 | 299,685 | 288,983 | 265,780 |
Total KMP | 354,504 | 0 | 6,558 | 870 | 361,932 | 361,689 | 401,799 | 373,071 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
23 Sep 2022 | Linda Barr appointed NED and Audit Chair | Added finance/ICT governance expertise; also a Tamawood and Veganic SKN NED |
16 Nov 2022 | Laurie Lefcourt retired | — |
31 May 2024 | Linda Barr resigned | Board reduced to three; Mr Dudurovic assumed Audit Chair |
FY2025–FY2026 | Lead audit partner rotation (Monaghan → Marti-Warren) | Routine |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | Ankla Pty Ltd (Mizikovsky associated) | 25,402,084 | 40.53 |
| 2 | Poltick Pty Ltd (Mizikovsky associated) | 15,168,557 | 24.20 |
| 3 | Kearney Ethical Investments Pty Ltd | 5,289,621 | 8.44 |
| 4 | Mr B M & Mrs M U D Kearney (Kearney Ethical Inv S/F) | 1,899,882 | 3.03 |
| 5 | Citicorp Nominees Pty Ltd (custodian) | 1,281,505 | 2.04 |
| 6 | BNP Paribas Nominees (IB AU Noms Retail) | 575,514 | 0.92 |
| 7 | Mr Edwin Giovanni Diaz | 540,140 | 0.86 |
| 8 | Mr Keith William Kerridge (Australasian Asset Mgmt) | 500,000 | 0.80 |
| 9 | The L and R Super Fund Pty Ltd | 472,562 | 0.75 |
| 10 | Melbourne Corporation of Australia Pty Ltd | 400,000 | 0.64 |
| — | Top 20 total | 54,510,704 | 86.97 |
Competitive Landscape
Key Competitors
| Competitor | HQ | Competing products | Relative positioning vs ANO |
|---|---|---|---|
BASF SE | Germany | Z-COTE zinc oxide range; organic UV filters | Global scale and formulation support; diversified filter portfolio |
Croda International plc | UK | Solaveil mineral UV dispersions | Premium dispersions; strong brand-owner relationships |
dsm-firmenich | Switzerland/Netherlands | PARSOL ZX zinc oxide; organic filters | Full UV-filter portfolio |
Merck KGaA (EMD Electronics/Surface Solutions) | Germany | Eusolex mineral filters; effect pigments | Effect-pigment overlap with White Sapphire |
Kobo Products Inc. | USA (private) | Zinc oxide and TiO2 dispersions | Direct dispersion competitor in US |
Sakai Chemical Industry | Japan | Fine zinc oxide (FINEX) | Asian scale; cited by ANO as tariff-exposed |
Tayca Corporation | Japan | Micro-particle zinc oxide and TiO2 | Asian incumbent |
Sumitomo Osaka Cement | Japan | Zinc oxide cosmetic dispersions | Japanese competitor |
Grillo-Werke AG | Germany (private) | Pharmaceutical-grade zinc oxide (FDA-listed) | API-grade powder competitor |
EverZinc | Belgium (private) | Zinc oxide powders | Commodity-to-specialty zinc oxide |
Zochem LLC | USA | Zinc oxide API (FDA 483, Nov 2024, per GKS record) | US domestic API producer |
Chinese / Asian low-cost zinc oxide importers | Various | Commodity zinc oxide | Price competition; ANO alleges TGA non-compliance in Australia |
Peer Comparison FY2026
| Metric | Advance ZincTek (FY2026, Jun) | BASF (FY2024, group) | Croda (FY2024, group) | dsm-firmenich (FY2024, group) |
|---|---|---|---|---|
Group revenue | A$13.1m | About €65bn | About £1.6bn | About €12.8bn |
Revenue growth | +12.6% | Not segment-comparable | Not segment-comparable | Not segment-comparable |
Relevant UV-filter revenue | About A$11.5m (ZinClear) | — | — | — |
Margin (EBITDA) | 31.3% (derived) | Not segment-comparable | Not segment-comparable | Not segment-comparable |
R&D intensity | Capitalised development 5.6% of revenue; total not disclosed | Not segment-comparable | Not segment-comparable | Not segment-comparable |
“—” = not publicly disclosed.
Recent Developments
There were no layoffs, guidance withdrawals or litigation against ANO in the period beyond the regulatory items noted. Items 14–16 are the most material; the FY2026 Annual Report does not mention them.*



